
Flexbumin®
Albumin Human Solution I.P. 20% /25%

November Edition

GUT-LIVER AXIS AND ALBUMIN: MODULATING SYSTEMIC INFLAMMATION

Targeting Immune Dysfunction, Endotoxemia, and Inflammatory Pathways in Cirrhosis



A focused clinical brief on integrating albumin therapy to modulate systemic inflammation, restore gut barrier function, and mitigate inflammation-driven complications in decompensated cirrhosis.

LEARNING OBJECTIVES

- **Gut–Liver Axis:** Understand the role of the gut–liver axis in cirrhosis-related systemic inflammation.[1,2]
- **Immunomodulatory & Detoxifying Properties:** Explain albumin's immunomodulatory and detoxifying properties.[1,4]
- **Bacterial Translocation & Endotoxemia:** Recognize how albumin impacts bacterial translocation and endotoxemia.[1,2]
- **Clinical Application in Inflammation:** Apply albumin therapy in inflammation-driven complications of liver disease.[1-5]

THE GUT–LIVER AXIS & SYSTEMIC INFLAMMATION IN CIRRHOSIS

Systemic inflammation in advanced liver disease is primarily propagated by disruption of the gut mucosal barrier and persistent immune activation.[1,2]

- Pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharides (LPS), translocate from the intestinal lumen into the portal circulation due to increased gut permeability and altered microbiota composition.[1,2]
- Translocated endotoxins trigger immune dysregulation and hyperactivation of circulating leukocytes, unleashing a cascade of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β)[1,2]
- Persistent inflammation exacerbates peripheral vasodilation, promotes endothelial dysfunction, and drives the clinical progression toward acute-on-chronic liver failure (ACLF).[1,2]

ALBUMIN'S IMMUNOMODULATORY & DETOXIFYING PROPERTIES (NON-ONCOTIC MECHANISMS)

Beyond its standard role in intravascular volume expansion (oncotic effect), albumin exerts distinct non-oncotic pleiotropic properties that function as a principal circulating scavenger and antioxidant to modulate inflammatory cascades in cirrhosis.[1,2]

Endotoxin Binding & Scavenging (Non-Oncotic)

- Albumin directly binds and neutralizes endotoxins, pathogen products, and lipopolysaccharides, thereby reducing free circulating inflammatory mediators.[1,2]
- Its high-affinity binding capacity prevents inflammatory ligands from activating toll-like receptor 4 (TLR4) pathways on immune cells.[1,2]

Immune Modulation & Antioxidant Effects (Non-Oncotic)

- Albumin maintains crucial systemic homeostasis by acting as a potent scavenger, antioxidant, and immunomodulatory molecule.[1]
- It predominantly circulates in a reduced state, featuring a free thiol group at the Cys34 residue that actively scavenges reactive oxygen and nitrogen species.[1]
- Albumin further restricts oxidative stress damage by binding and neutralizing free copper and iron ions.[1]
- By suppressing oxidative stress and cytokine hyperactivation, albumin preserves host immune responsiveness while attenuating destructive systemic inflammation.[1]

CLINICAL APPLICATIONS IN INFLAMMATION-DRIVEN COMPLICATIONS

Targeting systemic inflammation with albumin in combination with standard-of-care medical therapies is an established strategy to prevent organ dysfunction and manage acute decompensation events.[1,2]

- **Spontaneous Bacterial Peritonitis (SBP):** Administering intravenous **albumin in combination with antibiotic therapy** suppresses severe systemic inflammatory responses, preventing acute kidney injury and reducing overall mortality.[3]
- **Non-SBP Infections & Acute Decompensation:** Albumin therapy mitigates infection-induced inflammatory surges, stabilizing systemic hemodynamics and attenuating progression to multiorgan failure.[4,5]
- **Hepatorenal Syndrome (HRS-AKI):** Combined treatment of albumin with vasoconstrictors (terlipressin or norepinephrine) counteracts both systemic vasodilation and inflammation-mediated renal hypoperfusion.[4]

CLINICAL PEARL

The gut-liver axis is a primary engine of systemic inflammation in cirrhosis. Albumin serves not only as a hemodynamic volume expander, but also as an active immunomodulatory agent that neutralizes endotoxins and regulates oxidative stress.[1-5]

By scanning the code, you will be directed to the API of Flexbumin, an external website which is owned and managed by Takeda

API of Flexbumin

*The cases presented are hypothetical in nature and intended for illustrative purposes only. The management strategies discussed are evidence-based and aligned with established clinical guidelines and scientific literature.

Disclaimer:
This information is solely intended for the use of Registered Healthcare Practitioner / Registered Medical Practitioners only. This information should not be used, shared, or distributed to any other person / party and should be strictly used by the intended parties for the intended purposes only. Registered Healthcare Practitioner / Registered Medical Practitioner shall apply their independent medical judgment for assessing any patient. Takeda makes no representation or warranty concerning the information / content provided, and assumes no responsibility for the accuracy of the information or content or for any opinion furnished or any outcome based on the application of such information. This material contains copyright protected information, content; the use of which is limited by law and this material cannot be reproduced, replicated, used or modified by any person for their own use or further distribution. For more information, please refer to full

TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. Flexbumin® is a trademark or registered trademark of Baxalta Incorporated. Copyright © 2026 Takeda Pharmaceutical Company. All Rights Reserved.*

References:
1. Bernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O'Brien AJ, Trebicka J, Thevenot T, Arroyo V. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020 Jun;69(6):1127-1138. doi: 10.1136/gutjnl-2019-318843. Epub 2020 Feb 26. PMID: 32102926; PMCID: PMC7282556. **2.** Hasa E, Hartmann P, Schnabl B. Liver cirrhosis and immune dysfunction. Int Immunol. 2022 Sep 6;34(9):455-466. doi: 10.1093/intimm/dxac030. PMID: 35792761; PMCID: PMC9447994. **3.** Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999 Aug 5;341(6):403-9. doi: 10.1056/NEJM199908053410603. PMID: 10432325. **4.** Tufoni M, Baldassarre M, Zaccherini G, Antognoli A, Caraceni P. Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. Curr Hepatol Rep. 2020;19(3):147-158. doi: 10.1007/s11901-020-00521-1. Epub 2020 Jul 1. PMID: 32837825; PMCID: PMC7326530. **5.** Arroyo V, Garcia-Martinez R, Salvatella, X Human serum albumin, systemic inflammation, and cirrhosis Journal of Hepatology, 2014; 61, 396-407

AKI: Acute Kidney Injury **ACLF:** Acute-on-Chronic Liver Failure **Cys34:** Cysteine-34 **EABV:** Effective Arterial Blood Volume **EASL:** European Association for the Study of the Liver **HRS:** Hepatorenal Syndrome **HRS-AKI:** Hepatorenal Syndrome-Acute Kidney Injury **IL-1β:** Interleukin-1 Beta **IL-6:** Interleukin-6 **LPS:** Lipopolysaccharide **PAMPs:** Pathogen-Associated Molecular Patterns **PICD:** Paracentesis-Induced Circulatory Dysfunction **RAAS:** Renin-Angiotensin-Aldosterone System **ROS:** Reactive Oxygen Species **SBP:** Spontaneous Bacterial Peritonitis **TLR4:** Toll-Like Receptor 4 **TNF-α:** Tumor Necrosis Factor Alpha.

C-ARROW/INT/FLEX/0374 02 November, 2026